Introduction
Therapies for glioblastomas and primary central nervous system lymphomas (PCNSLs) differ, making it especially important to correctly diagnose these tumors. It is sometimes difficult to distinguish them on routine imaging studies and most patients receive pathological confirmation prior to treatment (Fig. 1) .
In 1 H-magnetic resonance spectroscopy (MRS), both glioblastomas and PCNSLs usually show depression of the creatine (Cr) peaks, elevation of the choline (Cho) peak, and elevation of the lipid (Lip) and/or lactate peak. With regard to Lip, PCNSLs have been reported to show higher Lip/Cr ratios from the contrast-enhancing regions than glioblastomas in which the voxel could be placed in solid tissue without macroscopic evidence of necrosis [1] . But it is often difficult to set voxels excluding the necrotic area, especially in glioblastomas. As for Cho, PCNSLs have been reported to show higher Cho/Cr ratios from the contrast-enhancing regions than glioblastomas [1] , while another study found that Cho/Cr ratios from the contrastenhancing regions do not differ significantly between them [2] . These results emphasize that the patterns of 1 H-MRS in glioblastomas and PCNSLs are diverse, indicating the need to evaluate other peaks to distinguish them more precisely.
With regard to glutamate (Glu), almost 85 % of all synapses in the brain are glutamatergic, making Glu a central molecule in the brain [3] . Besides its role in neurotransmission, Glu is a key molecule in synapse formation, dendrite pruning, cell migration, differentiation, and death [4] . As for glutamine (Gln), Glu and Gln are metabolites of the same metabolic pathway. For example, extracellular Glu released from the neuron is avidly taken up by the Glu transporters in glial cells, and Glu is rapidly converted to Gln by Gln synthetase in the glial cells. With in vivo 1 H-MRS, Glu and Gln are usually collectively evaluated by Glu+Gln. Because the chemical shift difference between Glu and Gln in 1 H-MRS is small, it can be difficult to distinguish them (Fig. 1d, e) . The independent quantification of Glu and Gln can be considerably improved by moving from 1.5T to 3T. With regard to Glu+Gln, it has been reported that Glu+Gln/Cr ratios from contrast-enhancing regions do not differ significantly between glioblastomas and PCNSLs [2] . No differences in Glu or Gln alone in in vivo 1 H-MRS between them have been reported, to the extent that we could determine.
On the other hand, it has been reported that in highgrade gliomas (World Health Organization grades III and IV), microdialysates in the tumor periphery consistently show significantly higher extracellular Glu relative to microdialysates in non-tumoral regions, unlike PCNSL [5] . And, high extracellular Glu has been noted to stimulate Gln synthetase and promote the synthesis of Gln from Glu in cultured astrocytes [6] .
Based on these reports, we hypothesized that in glioblastomas, due to high extracellular Glu, the synthesis of Gln from Glu would be promoted [6] , and so Glu/Glu+Gln ratios might be lower than those in PCNSLs. The purpose of this study was to analyze the differences in the 1 H-MRS A 71-year-old man. Mass formation was present on the left temporal lobe (a). The mass lesion showed definite hyper intensity on DWI (b), and a low ADC value (c). So in magnetic resonance imaging (MRI), because of high intensity on DWI and the low ADC value, primary central nervous system lymphoma (PCNSL) was suspected [16, 17] . In 1 H-MRS, Glu/Cr ratio indicated glioblastoma [Glu/Cr ratio = 2.080 (<2.509)], Glu/Glu+Gln ratio indicated PCNSL [Glu/Glu+Gln ratio = 0.587 (>0.558)]. In the present study, about 31 % of glioblastomas showed Glu/Glu+Gln ratio >0.558, about 92 % of glioblastomas showed Glu/Cr ratio <2.509. So in this case, glioblastoma was suspected in 1 H-MRS. Eventually, glioblastoma was confirmed histopathologically findings among glioblastomas and PCNSLs with special reference to Glu and Gln expression.
Materials and methods

Patients
This retrospective analysis of the data was approved by the institutional review board of our university. All patients gave informed consent prior to inclusion in this study. All patients were introduced to our institution for further examination of their brain tumors from April 2011 to June 2014. All of them had normal immunocompetence. The study focused on 31 patients with glioblastoma and 15 patients with PCNSL. The diagnosis was verified by stereotactic biopsy, endoscopic transventricular biopsy, open biopsy, and surgical resection. Clinical parameters in the analyzed groups are summarized in Table 1 . All tumors were confirmed histopathologically after preoperative diagnosis with magnetic resonance imaging (MRI) and 1 H-MRS, and were not subjected to biopsy, surgical resection, chemotherapy or radiation therapy before the preoperative diagnosis with MRI and 1 H-MRS. We excluded the cases in which the lesion was <1 cm in diameter, with 1 case diagnosed as PCNSL thus excluded. Two patients with glioblastoma and 7 with PCNSL had multiple mass lesions in the brain, and these patients were subjected to 1 H-MRS in only 1 mass lesion each. So, in the present study, we used only one set of data for each patient. When multiple mass lesions were present, we determined the mass lesion that seemed the most suitable for gaining reliable 1 H-MRS (size, homogenous lesion, and so on).
H-MR spectroscopic acquisition protocols
MRI and single voxel
1 H-MRS examinations were performed on a SIGNA HDxt 3.0T MR scanner (GE Healthcare) using a standard quadrature head coil. Spectroscopic imaging studies were performed after contrast injection in all patients [intravenous administration of 0.1 mmol per kilogram of body weight of gadolinium-based contrast material (Gd-DTPA Magnevist; Schering, Berlin, Germany, or Gd-DTPA-BMA Omniscan; Nycomed, Oslo, Norway)]. Point-resolved single voxel spectroscopy (PRESS) was used to obtain 1 H-MRS using repetition time (TR) at 1500 ms, echo time (TE) at 35 ms, and number of excitations (NEX) = 128. Water suppression and fat suppression were done on default [3-pulse chemical shift selection suppression (CHESS)]. Size and position of volume of interest (VOI) were determined by examining the MR images in all three dimensions (sagittal, coronal, and transverse planes). The size of a VOI (3.7-32.6 ml) was changed according to the size of the lesions. Voxels were centered in the area of contrast-enhancement when present, with minimal contamination from the surrounding non-tumoral tissue, based on the initial screening examination. Outer volume suppression (OVS) around the VOI was added if needed ( Fig. 2) . To avoid bias, we did not exclude any cases due to improper positioning of the VOI.
The tumor shapes were variable, often making it difficult to exclude necrotic and surrounding normal areas (Fig. 2) . So, to compare the differences in the necrotic area in the VOIs between glioblastomas and PCNSLs, first we defined the lesion surrounded by enhanced lesion as 'tumor' temporarily. Then we counted pixels within the VOI and calculated the ratio between the area of unenhanced lesion in the 'tumor' and the area of whole 'tumor' in the VOI. And, to compare the differences in the surrounding normal area in the VOI between glioblastomas and PCNSLs, we calculated the ratio between the area of 'tumor' and the area of the VOI. We measured Cr as a constituent of all cells, Cho as an indicator of phospholipid membrane turnover, Lip as an indicator of cellular destruction and lipid-laden cells, Glu+Gln as a major neurotransmitter and its metabolite, and Glu alone. Cr, Cho, Lip at 1.3 parts per million (ppm) [Lip (1.3 ppm)], Glu+Gln and Glu were determined using Linear Combination of Model spectra (LCModel; S Provencher, Canada) (Version 6.3-0C; this version is available for lipid of tumor option) [7, 8] . Estimated concentrations with Cramer-Rao lower bounds (CRLB) of below 20 % standard deviation (SD) were regarded as recommended in the original published model [7, 8] . The selection of metabolites depending on % SD might result in the exclusion of low concentration metabolites, possibly biasing the results. So, we showed the results of both unselected and selected data depending on % SD in this study. Necrosis is characteristic of glioblastomas [9] , which makes it difficult to set the voxel in solid tissue without macroscopic evidence of necrosis (Fig. 2) . And, because of cellular loss due to necrosis, comparing metabolites among these tumors using absolute concentrations is problematic. Cr has often been regarded as a stable metabolite and has subsequently been used as a reference metabolite. So in the present study, to compare metabolites among these tumors, we used Cho/Cr, Lip (1.3 ppm)/Cr, Glu+Gln/Cr, and Glu/ Cr ratios of each tumor, and the absolute concentration of Cr was compared among these tumors. And, to compare differences in Glu-Gln cycles among these tumors, we used Glu/Glu+Gln. With the LCModel, values of Glu, Glu+Gln and Gln are obtained automatically. Regarding Gln, Gln at estimated concentrations with CRLB of below 20 % SD could be distinguished in only a few cases in PCNSLs. And to avoid the effect of cellular loss by necrosis, we did not use absolute concentrations of Glu and Glu+Gln, but used their ratios. These analyses and calculations were performed by a physician who was aware of the nature of the study and clinical data.
Statistical analysis
Differences in the absolute concentration of Cr, Cho/Cr, Lip (1.3 ppm)/Cr, Glu+Gln/Cr, Glu/Cr, and Glu/Glu+Gln ratios among groups were evaluated with Mann-Whitney U tests. P values <0.05 were considered statistically significant. The value at which the receiver operating characteristic (ROC) curve was closest to point (0, 1) was considered as the optimum threshold value. All analyses were performed with the open-source software for statistical computing and graphics (R, version 2.5, Department of Statistics and Mathematics, University of Vienna, Vienna, Austria; http://www.r-project.org) by a physician who was aware of the nature of the study and clinical data.
Results
The differences in VOIs between glioblastomas and PCNSLs are summarized in Table 2 . The number of cases whose ratios at estimated concentrations with CRLBs of below 20 % SD in the analyzed groups is summarized in Table 3 . Values of ratios in the analyzed groups (mean ± SD) and P values of ratios between the analyzed groups are summarized in Table 4 (CRLB of all % SD) and Table 5 (CRLB of below 20 % SD). The scatter plots are shown in Fig. 3 (CRLB of all % SD) and Fig. 4 (CRLB of below 20 % SD).
VOI
Regarding the ratio between the area of unenhanced lesion in 'tumor' and the area of whole 'tumor' in the VOI, glioblastomas showed significantly higher values compared to PCNSLs (P < 0.001). For the ratio between the area of 'tumor' and the area of the VOI, the difference between glioblastomas and PCNSLs was not significant (P = 0.320).
Cr in 1 H-MRS (CRLB of all % SD)
PCNSLs showed significantly lower Cr values compared to glioblastomas (P = 0.010).
Cr in 1 H-MRS (CRLB of below 20 % SD)
The difference between glioblastomas and PCNSLs was not significant (P = 0.234).
Cho/Cr in 1 H-MRS (CRLB of all % SD)
PCNSLs showed significantly higher Cho/Cr ratios compared to glioblastomas (P = 0.001).
Cho/Cr in 1 H-MRS (CRLB of below 20 % SD)
PCNSLs showed significantly higher Cho/Cr ratios compared to glioblastomas (P = 0.026). Cho/Cr ratios of greater than 0.627 as an indicator of PCNSLs rather than glioblastomas showed a sensitivity of 100 % (13/13) and a specificity of 35 % (10/29) (Fig. 4) .
Lip (1.3 ppm)/Cr in 1 H-MRS (CRLB of all % SD)
PCNSLs showed significantly higher Lip (1.3 ppm)/Cr ratios compared to glioblastomas (P = 0.008).
Lip (1.3 ppm)/Cr in 1 H-MRS (CRLB of below 20 % SD)
There were no significant differences between glioblastomas and PCNSLs (P = 0.431).
Lipid shows a wide peak. With LCModel, for differences in chemical shift (ppm), lipid peak values are obtained at 2.0, 1.3, and 0.9 ppm. In the present study, we used only Lip (1.3 ppm)/Cr. Because both Lip (2.0 ppm)/Cr and Lip (0.9 ppm)/Cr at estimated concentrations with CRLB of below 20 % SD could be distinguished in only a few cases, it was difficult to compare the values of Lip (2.0 ppm)/Cr and Lip (0.9 ppm)/Cr among the analyzed groups.
Lactate (Lac) is a marker of the anaerobic metabolic state of tumors. Lac/Cr at estimated concentrations with CRLB of below 20 % SD could be distinguished in only a few cases in lymphomas.
Glu+Gln/Cr in 1 H-MRS (CRLB of all % SD)
PCNSLs showed significantly higher Glu+Gln/Cr ratios compared to glioblastomas (P = 0.004).
Glu+Gln/Cr in 1 H-MRS (CRLB of below 20 % SD)
The difference between glioblastomas and PCNSLs was not significant (P = 0.099).
Glu/Cr in 1 H-MRS (CRLB of all SD)
PCNSLs showed significantly higher Glu/Cr ratios compared to glioblastomas (P < 0.001).
Glu/Cr in 1 H-MRS (CRLB of below 20 % SD)
PCNSLs showed significantly higher Glu/Cr ratios compared to glioblastomas (P = 0.003). Glu/Cr ratios of greater than 2.509 as an indicator of PCNSLs rather than glioblastomas showed a sensitivity of 88 % (7/8) and a specificity of 92 % (22/24) (Fig. 4) . 
Glu/Glu+Gln in 1 H-MRS (CRLB of all SD)
Glioblastomas showed significantly lower Glu/Glu+Gln ratios compared to PCNSLs (P < 0.001).
Glu/Glu+Gln in 1 H-MRS (CRLB of below 20 % SD)
Glioblastomas showed significantly lower Glu/Glu+Gln ratios compared to PCNSLs (P < 0.001). As an indicator of glioblastomas as compared to PCNSLs, Glu/Glu+Gln ratios <0.558 showed a sensitivity of 69 % (18/26) and a specificity of 100 % (13/13) (Fig. 4) . With LCModel, values of Glu, Glu+Gln and Gln are obtained automatically. Regarding Gln, Gln at estimated concentrations with CRLB of below 20 % SD could be distinguished in 18 of 31 glioblastomas (58 %), but only in 2 of 15 PCNSLs (13 %). This made it difficult to compare their Gln values (Figs. 5, 6 ). Fig. 3 The data depending on CRLB of all % SD. Absolute concentration of Cr (a), Cho/ Cr ratios (b), Lip(1.3 ppm)/ Cr ratios (c), Glu+Gln/Cr ratios (d), Glu/Cr ratios (e), and Glu/Glu+Gln ratios (f) in the analyzed groups. Asterisk significant difference (P < 0.05) between the analyzed groups, P values were determined with Mann-Whitney U tests. GBM glioblastoma, PCNSL primary central nervous system lymphoma
Discussion
Several studies have reported differences between glioblastomas and PCNSLs in 1 H-MRS [1, 2] . In the present study, Cho/Cr, Glu/Cr, and Glu/Glu+Gln ratios showed significant differences between glioblastomas and PCNSLs among both unselected and selected data depending on % SD.
The selection of metabolites depending on CRLB of below 20 % SD might result in the exclusion of low concentration metabolites, so we showed the results of both unselected and selected data depending on % SD. In LCModel, use of the data depending on CRLB of below 20 % SD is recommended [7, 8] .
Cr has often been regarded as a stable metabolite, and has subsequently been used as a reference metabolite in 1 H-MRS. In this study, glioblastomas contained a significantly larger necrotic area in the VOI as compared to PCNSLs. So, to compare metabolites among these tumors, we used not absolute concentrations but rather ratios between metabolites and Cr. Among unselected data depending on % SD, PCNSLs showed significantly lower Cr values Fig. 4 The data depending on CRLB of below 20 % SD. Absolute concentration of Cr (a), Cho/Cr ratios (b), Lip(1.3 ppm)/Cr ratios (c), Glu+Gln/Cr ratios (d), Glu/ Cr ratios (e), and Glu/Glu+Gln ratios (f) in the analyzed groups. Glu/Cr ratios of greater than 2.509 as an indicator of PCNSLs rather than glioblastomas showed a sensitivity of 88 % (7/8) and a specificity of 92 % (22/24). As an indicator of glioblastomas as compared to PCNSLs Glu/Glu+Gln ratios <0.558 showed a sensitivity of 69 % (18/26) and a specificity of 100 % (13/13). Asterisk significant difference (P < 0.05) between the analyzed groups, P values were determined with Mann-Whitney U tests. GBM glioblastoma, PCNSL primary central nervous system lymphoma 1 H-MRS in a case of PCNSL. Glu peak is prominent compared to Gln peak 1 H-MRS in a case of glioblastoma. Glu peak is lower than in Fig. 5 , and Gln peak resembles Glu peak compared to glioblastomas, and so it would not be proper to use Cr as a reference metabolite for comparing glioblastomas and PCNSLs. Unlike data depending on below 20 % SD, PCNSLs showed significantly higher Cho/Cr, Lip (1.3 ppm)/Cr, and Glu+Gln/Cr ratios compared to glioblastomas in unselected data depending on % SD, but it would be difficult to conclude whether these results are useful. On the other hand, among selected data depending on CRLB of below 20 % SD, the absolute concentration of Cr did not differ significantly between glioblastomas and PCNSLs.
Both glioblastomas and PCNSLs usually show elevation of Cho/Cr in 1 H-MRS. PCNSLs have been reported to show higher Cho/Cr ratios than glioblastomas [1] , while another study found that Cho/Cr ratios do not differ significantly between them [2] . In the present study, PCNSLs showed significantly higher Cho/Cr ratios as compared to glioblastomas, though the difference in Cho/Cr was smaller than that in Glu/Cr and Glu/Glu+Gln. The increased Cho peak in studies of tumors has been attributed to increased cellularity and rapid membrane turnover [10] . And it has been reported that PCNSLs have significantly lower apparent diffusion coefficient (ADC) values compared to glioblastomas due to their higher cellularity [11, 12] . Such a difference in cellularity might have affected the results.
It has been reported that PCNSLs have higher Lip/ Cr than glioblastomas in which the voxel could be placed without macroscopic evidence of necrosis [1] . In this report, glioblastomas from which VOI contained macroscopically evident necrosis showed massively elevated Lip/ Cr compared to glioblastomas from which VOI did not contain macroscopic evidence of necrosis [1] . In the present study, VOIs were centered in non-necrotic parts of the tumors, but could contain some necrotic parts, especially in glioblastomas. And in the present study, although lipid shows a wide peak, we could evaluate differences only at 1.3 ppm. These results may be related to the fact that Lip/ Cr did not differ between glioblastomas and PCNSLs significantly among selected data depending on below 20 % SD in the present study.
With regard to Glu and Gln, Glu is largely synthesized de novo in the neurons and glial cells. Extracellular Glu released from neurons into the synaptic cleft is avidly taken up by the Glu transporters in glial cells, and Glu is rapidly converted to Gln by Gln synthetase in the glial cells [4, 13, 14] . It has been reported that extracellular Glu accumulation is induced as a result of decreased functional glial Glu transporter activity in glioblastomas [15, 16] . It has also been reported that high extracellular Glu inhibits glial Glu transporter expression and stimulates Gln synthetase expression in cultured astrocytes [6] . In other words, glioblastomas show elevated levels of extracellular Glu as a result of decreased functional glial Glu transporter activity. In surrounding glial cells, high extracellular Glu inhibits uptake of Glu, thereby leading to further increases in extracellular Glu, while high extracellular Glu stimulates Gln synthetase expression and promotes the synthesis of Gln from Glu. In this way, Glu/Glu+Gln ratios in glioblastomas might decrease as compared with those in normal glial cells. We could not find any pertinent studies regarding the Glu-Gln cycle in PCNSLs.
As for Glu+Gln/Cr, a significant relation has been identified between the tissue Glu+Gln concentration and glucose metabolism in human cortex using 18F-2-fluoro-2-deoxy-d-glucose positron emission tomography ( 18 F-FDG PET) and 1 H-MRS [17] , with PCNSLs found to have significantly higher SUV max and SUV average than highgrade gliomas and brain metastases with 18 F-FDG PET [18] . In the present study, though the difference was not significant, PCNSLs tended to show higher Glu+Gln/Cr ratios compared to glioblastomas, while Cr did not differ significantly between them. These results may be attributable to the fact that glucose metabolism and Glu+Gln concentration are in some way related in the cerebral cortex and that PCNSLs show significantly higher SUV max in 18 F-FDG PET as compared to high-grade gliomas.
With regard to Glu/Cr, PCNSLs showed significantly higher Glu/Cr relative to glioblastomas in the present study. This would appear to be due to their significantly higher Glu/Glu+Gln and higher Glu+Gln/Cr (but not statistically significant) compared to those of glioblastomas.
In this study, there were significant differences between glioblastomas and PCNSLs in Glu/Cr and Glu/Glu+Gln. This might be attributable to some differences in the GluGln cycle and glucose metabolism. But several other factors also seem to have contributed to these results. For example, in this study, glioblastomas contained more necrotic lesions than PCNSLs, which might have affected the results. And it has been reported that PCNSLs have lower significantly ADC values compared to glioblastomas due to their higher cellularity [11, 12] . Such a difference in cellularity might have affected the results.
About absolute concentrations of metabolites in tumors as determined by in vitro 1 H-MRS, it has been reported that glioblastomas show very increased glycine concentration and PCNSLs show 4-5 times increased phosphorylethanolamine (PEA) concentration as compared with normal brain [19] . Glycine and PEA are not obtained automatically with LCModel, and so we did not evaluate them in the present study.
The following limitations were present in the present study. First, it was retrospective in nature, and the number of patients was limited. Second, the physician who performed the analyses and calculations was not blinded to the clinical data. Third, there is difficulty in resolving Glu and Gln from Glu+Gln in 1 H-MRS. Because the chemical shift difference between Glu and Gln in 1 H-MRS is small, it can be difficult to distinguish the two metabolites (Fig. 1d, e) . In this study, we showed the results of both unselected and selected data depending on % SD. In PCNSLs and healthy participants, Gln/Cr that met this criterion could be distinguished in only a few cases. So, we could not evaluate Gln/Cr among the analyzed groups. Fourth, contrast material may affect 1 H-MRS. An average 15 % decrease in the peak area of Cho-containing compounds after administration of contrast material has been reported [20, 21] . And, it has been noted that the influence of contrast medium on MR spectroscopy differs depending on the structure of the component, with GD-DTPA more efficient in enhancing relaxation of Cho than GD-DOTA and GD-DTPA-BMA [22] . In this study, we used a different type of contrast medium in each patient, and so the results may have been influenced by the type of contrast medium. Another study found no statistically significant differences before and after contrast in the Cho peak area in the tumor, nor in the contralateral hemisphere [23] . With regard to Glu+Gln and Glu, we could not find any relevant studies, and so cannot draw any conclusions about the effect of contrast material on them. In the present study, 1 H-MRS studies were performed after contrast injection in all patients because abnormal enhancement seems to be useful in guiding VOI localization. Fifth, in single voxel 1 H-MRS, the VOI may contain not only tumors but also peritumoral lesions. In the present study, to avoid peritumoral lesions as much as possible, OVS around the VOI was added if needed. And the difference in the surrounding normal area in the VOI between glioblastoma and PCNSL was not significant. Sixth, it was difficult to set the voxel in solid tissue without macroscopic evidence of necrosis, especially in glioblastomas. Because of cellular loss due to necrosis, comparing metabolites among these tumors using absolute concentrations seemed to be difficult, and so instead we compared the ratios of each metabolite with Cr. Seventh, in 1 H-MRS, estimated metabolic concentration ratios differ according to location. VOIs could contain various percentages of white matter and cortical gray matter. It has been reported that the estimated absolute concentrations of Cr, Glu, and Glu+Gln are higher in white matter than in cortical gray matter, but Glu+Gln/Cr and Glu/Cr are not so different between white matter and cortical gray matter as compared to Cho/Cr and N-acetyl aspartate (NAA)/Cr [24] . Eighth, point-resolved single voxel spectroscopy (PRESS) was used to obtain 1 H-MRS using repetition time (TR) at 1500 ms, and echo time (TE) at 35 ms. But TR = 1500 ms seems to be too short for accurate peak ratio evaluation due to the difference in T1 of each peak. Using a long TR of at least 4000 ms is recommended in the original published model [7, 8] .
In conclusion, our results suggest that Glu/Cr, Glu/ Glu+Gln, and Cho/Cr as determined by in vivo singlevoxel proton 1 H-MRS may be helpful in the differentiation of glioblastomas and PCNSLs. We anticipate that the precise mechanisms underlying these results will be elucidated in future studies.
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